This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT05371496 |
|---|---|
| Status | Completed |
| Phase | Phase 4 |
| Sponsor | Mayo Clinic |
| Enrollment | 81 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Cardiomyopathy; Heart Failure With Preserved Ejection Fraction (HFpEF); Obesity |
| Interventions | Semaglutide; Placebo; Counselling on healthy lifestyle intervention |
| Start | Sep 6, 2022 |
| Primary completion | Jul 17, 2026 |
| Study completion | Jul 17, 2026 |
| Results posted | Not yet |
| Registry last updated | Aug 14, 2026 |
| Collaborators | United States Department of Defense |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this research is to find out if an aggressive intervention to lose weight, will improve symptoms in patients with obesity-related cardiomyopathy, which is also known as the obese phenotype of heart failure with preserved ejection fraction (HFpEF).
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Pulmonary Capillary Wedge Pressure (PCWP) | Baseline, 12 months |
28 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 18, 2026. See the trial changes feed for what has changed recently.
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.